期刊
ADVANCED MATERIALS
卷 31, 期 17, 页码 -出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adma.201808294
关键词
chemotherapy; full-length antibodies; immunotherapy; membrane nanovesicles; theranostics
类别
资金
- National Science and Technology Major Project of Infectious Diseases [2018ZX10101001-002, 2017ZX10202203-001]
- Major State Basic Research Development Program of China [2017YFA0205201, 2018YFA0107301]
- National Natural Science Foundation of China [81422023, 81603015, 81871404, U1705281, U1505221]
- Fundamental Research Funds for the Central Universities [20720160065, 20720150141]
- Program for New Century Excellent Talents in University, China [NCET-13-0502]
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [ZIAEB000073] Funding Source: NIH RePORTER
The ability to selectively kill cancerous cell populations while leaving healthy cells unaffected is a key goal in oncology. The use of nanovesicles (NVs) as chemotherapeutic delivery vehicles has been recently proven successful, yet monotherapy with monomodalities remains a significant limitation for solid tumor treatment. Here, as a proof of principle, a novel cell-membrane-derived NVs that can display full-length monoclonal antibodies (mAbs) is engineered. The high affinity and specificity of mAb for tumor-specific antigens allow these vesicular antibodies (VAs) to selectively deliver a cytotoxic agent to tumor cells and exert potent inhibition effects. These VAs can also regulate the tumor immune microenvironment. They can mediate antibody-dependent cellular cytotoxicity to eradicate tumor cells via recruitment and activation of natural killer cells in the tumor. Upon further encapsulation with chemotherapeutic agents, the VAs show unequaled cooperative effects in chemotherapy and immunotherapy in tumor-bearing mice. As far as it is known, this is the first report of a VA-based multifunctional combination therapy platform. This might lead to additional applications of vesicular antibodies in cancer theranostics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据